

Miguel Munoz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3761963/miguel-munoz-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66
papers

1,950
citations

27
h-index

43
g-index

72
ext. papers

2,273
ext. citations

3.6
avg, IF

5.15
L-index

#	Paper	IF	Citations
66	The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.. <i>BioMed Research International</i> , 2022 , 2022, 6291504	3	0
65	Why use aprepitant only as a cough suppressant in lung cancer when at higher doses it could also exert an antitumor action?. <i>Archivos De Bronconeumologia</i> , 2022 ,	0.7	0
64	Prognostic Significance of Substance P/Neurokinin 1 Receptor and Its Association with Hormonal Receptors in Breast Carcinoma. <i>BioMed Research International</i> , 2021 , 2021, 5577820	3	2
63	Neurokinin receptor antagonism: a patent review (2014-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020 , 30, 527-539	6.8	8
62	The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	9
61	The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study. <i>European Journal of Histochemistry</i> , 2020 , 64,	2.1	4
60	Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach. <i>Mini-Reviews in Medicinal Chemistry</i> , 2020 , 20, 408-417	3.2	3
59	The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?. <i>Cancers</i> , 2020 , 12,	6.6	19
58	Neurokinin-1 Receptor Antagonists against Hepatoblastoma. <i>Cancers</i> , 2019 , 11,	6.6	8
57	Neurokinin-1 receptor antagonist aprepitant and radiotherapy, a successful combination therapy in a patient with lung cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2019 , 11, 50-54	1.6	12
56	Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose. <i>Acta Dermato-Venereologica</i> , 2019 , 99, 620-621	2.2	7
55	Neurokinin-1 Receptor Antagonists as Anticancer Drugs. <i>Letters in Drug Design and Discovery</i> , 2019 , 16, 1110-1129	0.8	4
54	Glioma and Neurokinin-1 Receptor Antagonists: A New Therapeutic Approach. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019 , 19, 92-100	2.2	3
53	Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists. <i>Investigational New Drugs</i> , 2019 , 37, 17-26	4.3	10
52	Substance P 2018 , 571-578		1
51	Immunolocalization of Substance P and NK-1 Receptor in ADIPOSE Stem Cells. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 4686-4696	4.7	7
50	Increased nuclear localization of substance P in human gastric tumor cells. <i>Acta Histochemica</i> , 2017 , 119, 337-342	2	7

49	The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines. <i>Pharmacological Reports</i> , 2017 , 69, 696-701	3.9	9
48	Immunolocalization of substance P and NK-1 receptor in vascular anomalies. <i>Archives of Dermatological Research</i> , 2017 , 309, 97-102	3.3	2
47	Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy. <i>Letters in Drug Design and Discovery</i> , 2017 , 14,	0.8	2
46	Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 425-31	4.8	23
45	Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach. <i>Saudi Journal of Gastroenterology</i> , 2016 , 22, 260-8	3	20
44	The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. <i>Journal of Biosciences</i> , 2015 , 40, 441-63	2.3	60
43	Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach. <i>Cancers</i> , 2015 , 7, 1215-32	6.6	11
42	Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. <i>Journal of Hepatology</i> , 2014 , 60, 985-94	13.4	72
41	Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor. <i>Peptides</i> , 2014 , 55, 1-12	3.8	6
40	Involvement of substance P and the NK-1 receptor in human pathology. <i>Amino Acids</i> , 2014 , 46, 1727-50	3.5	117
39	Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts. <i>International Journal of Oncology</i> , 2014 , 44, 137-46	4.4	35
38	The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. <i>International Journal of Oncology</i> , 2014 , 45, 1658-72	4.4	44
37	Cancer progression and substance P. <i>Histology and Histopathology</i> , 2014 , 29, 881-90	1.4	31
36	Involvement of substance P and the NK-1 receptor in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2321-34	5.6	26
35	Involvement of substance P and the NK-1 receptor in cancer progression. <i>Peptides</i> , 2013 , 48, 1-9	3.8	92
34	Safety of neurokinin-1 receptor antagonists. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 673-85	4.1	34
33	Immunolocalization of substance P and NK-1 receptor in Hofbauer cells in human normal placenta. <i>Microscopy Research and Technique</i> , 2013 , 76, 1310-3	2.8	6
32	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013 , 4, 502-30	3.3	131

31	The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. <i>Investigational New Drugs</i> , 2012 , 30, 529-40	4.3	32
30	NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. <i>Expert Opinion on Therapeutic Patents</i> , 2012 , 22, 735-46	6.8	19
29	The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. <i>Peptides</i> , 2012 , 38, 318-25	3.8	49
28	The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. <i>Scientific World Journal, The</i> , 2012 , 2012, 381434	2.2	39
27	NK-1 receptor antagonists: a new generation of anticancer drugs. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012 , 12, 593-9	3.2	10
26	The NK-1 receptor: a new target in cancer therapy. <i>Current Drug Targets</i> , 2011 , 12, 909-21	3	62
25	NK-1 as a melanoma target. <i>Expert Opinion on Therapeutic Targets</i> , 2011 , 15, 889-97	6.4	14
24	NK-1 receptor antagonists: a new paradigm in pharmacological therapy. <i>Current Medicinal Chemistry</i> , 2011 , 18, 1820-31	4.3	40
23	The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. <i>Laboratory Investigation</i> , 2010 , 90, 1259-69	5.9	68
22	The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines. <i>Cancers</i> , 2010 , 2, 611-23	6.6	16
21	A new frontier in the treatment of cancer: NK-1 receptor antagonists. <i>Current Medicinal Chemistry</i> , 2010 , 17, 504-16	4.3	66
20	The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile. <i>Peptides</i> , 2010 , 31, 1643-8	3.8	10
19	Paravertebral anesthesia: how substance P and the NK-1 receptor could be involved in regional block and breast cancer recurrence. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 601-3	4.4	17
18	The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. <i>Investigational New Drugs</i> , 2010 , 28, 187-93	4.3	88
17	Immunolocalization of NK-1 receptor and Substance P in human normal placenta. <i>Placenta</i> , 2010 , 31, 649-51	3.4	17
16	Neurokinin-1 receptor: a new promising target in the treatment of cancer. <i>Discovery Medicine</i> , 2010 , 10, 305-13	2.5	27
15	Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. <i>Histopathology</i> , 2009 , 54, 258-60	7.3	40
14	A role for the substance P/NK-1 receptor complex in cell proliferation in oral squamous cell carcinoma. <i>Anticancer Research</i> , 2009 , 29, 2323-9	2.3	39

13	The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. <i>Tumor Biology</i> , 2008 , 29, 245-54	2.9	80
12	NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEP-2. <i>Investigational New Drugs</i> , 2008 , 26, 111-8	4.3	69
11	Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138. <i>Investigative Ophthalmology and Visual Science</i> , 2007 , 48, 2775-81		49
10	Kluyvera meningitis in a newborn. <i>Pediatric Infectious Disease Journal</i> , 2007 , 26, 1070-1	3.4	16
9	The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines. <i>Letters in Drug Design and Discovery</i> , 2006 , 3, 323-329	0.8	29
8	The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. <i>Neuropeptides</i> , 2005 , 39, 427-32	3.3	77
7	Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. <i>Investigative Ophthalmology and Visual Science</i> , 2005 , 46, 2567-70		51
6	Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. <i>Melanoma Research</i> , 2004 , 14, 183-8	3.3	57
5	Resistance to a beta-lactam antibiotic appearing during therapy for enterobacter cloacae sepsis in a child. <i>Medical and Pediatric Oncology</i> , 2003 , 40, 62-3		
4	Primary leptomenigeal melanoma in a child. <i>Pediatric Neurology</i> , 2001 , 24, 390-2	2.9	20
3	Primary idiopathic chylopericardium in a 2 month old successfully treated without surgery. <i>Journal of Pediatric Surgery</i> , 2000 , 35, 646-8	2.6	10
2	Seizures caused by chloral hydrate sedative doses. <i>Journal of Pediatrics</i> , 1997 , 131, 787-8	3.6	10
1	Prognostic significance of Substance P/ Neurokinin 1 receptor and its association with hormonal receptors in breast carcinoma		1